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ABSTRACT
New techniques in regenerative medicine may soon
enable the creation of human organs inside animals
using induced pluripotent stem cells. This technology has
the potential to solve the organ scarcity problem by
providing a limitless source of personalised organs for
transplantation, but also raises several ethical issues,
particularly concerning animal welfare, the ‘human
features’ problem and human dignity.
INTRODUCTION
Cutting-edge animal research suggests that it will
soon be possible to grow human organs in animals
using induced pluripotent stem cells (iPSCs). iPSCs
derived from a patient who needs an organ can be
injected into a developing embryo of a different
species such as a pig, giving the resulting animal a
human kidney or other organ that can then be
transplanted into the patient. Organs from such
cross-species chimaeras have the potential to solve
the current organ scarcity problem, and to provide
organs that will not trigger a host immune reaction.
This article describes and analyses the potential of
these new techniques in regenerative medicine, and
the associated ethical issues.
THE ORGAN SCARCITY PROBLEM
Thousands of people die every year because there
are not enough organs available to meet demand.
In the UK alone, it is estimated that three people
die every day while waiting for an organ.1 As well
as the loss of life caused by the organ scarcity
problem, patients waiting for organs have a
reduced quality of life. Their suffering and in many
cases their avoidable premature deaths also have a
substantial negative effect on the quality of life of
their families, making organ scarcity a significant
societal problem. Despite various attempts in differ-
ent countries to increase deceased donation rates
via opt-out consent systems and incentives2 and the
altruistic actions of those who are willing to donate
organs while still alive, there appears to be little
prospect of meeting the demand for organs
without also creating them artificially (see table 1).
Three main routes towards the creation of viable
‘man-made’ organs have been pursued in recent
years: in vivo creation of organs via xenotrans-
plantation from genetically modified animals, in
vitro creation of ‘lab-grown’ organs and the con-
struction of bionic, mechanical organs. All three of
these avenues have hit substantial technical hurdles,
although research to overcome these obstacles is
ongoing. In this paper, we discuss the use of
pluripotent stem cells to create human organs
inside animals. This novel biotechnology poten-
tially offers two important advantages: it would
provide a new source of organs, and these organs
would be unlikely to be rejected by the recipients’
immune system. In addition, ‘chimaera organs’ are
highly likely to circumvent the problem of zoonosis
(generation of new cross-species viruses) posed by
other forms of xenotransplantation.
THE ROLE OF PLURIPOTENT STEM CELLS IN
REGENERATIVE MEDICINE
Pluripotent stem cells (PSCs) have two essential
properties. They can be expanded indefinitely
without loss of their developmental potential, a
process called self-renewal, and they can specialise
(differentiate) into any of the different cell types in
the body. As such, PSCs are viewed as a promising
cellular source for the replacement of cells, and
organs that are lost due to trauma or disease. Since
2006, these remarkable cells have been generated
in the lab as iPSCs through the reprogramming of
somatic cells such as skin cells.
The ability to derive iPSCs from the patient’s own
skin cells enables the possibility of personalised
regenerative therapies3–6 with minimal risk of tissue
rejection. Several clinical trials using human iPSCs
are currently underway: Takahashi’s macular
degeneration trial at the RIKEN Center for
Developmental Biology in Wako, Japan will start in
2014,7 and trials are in preparation in Japan to
explore the use of iPSC-derived blood platelets.8–10
In both these applications, transplantation of a
single PSC-derived cell type is sufficient for treat-
ment of the disease. In many instances, however,
pathology is the result of the loss of function of an
entire organ in which multiple cell types coordi-
nately function in an anatomically complicated
manner. While PSCs have the intrinsic ability to
form entire organs, doing so in a laboratory setting
has been extremely challenging. Recapitulating the
temporal and anatomical choreography that directs
the formation of complex organs such as the heart
or kidney appears to represent an almost impossible
challenge. The use of chimaeras could provide a
solution to this problem, as doing so would entail
growing PSC-derived human organs in an in vivo
system.
CREATING CHIMAERA ORGANS
Recently, the teams of Nakauchi and Okabe demon-
strated in a series of ground-breaking experiments
that interspecific chimaeras can be used to guide the
generation of entire complex organs, such as the
Clinical ethics















thics: first published as 10.1136/m






thymus or pancreas, from PSCs.11 12 In these studies, the
researchers injected rat pluripotent stem cells into mutant mouse
blastocysts and demonstrated that these cells integrate with the
murine embryo and contribute to the development of all
tissues.13 Furthermore, at locations where the murine cells fail to
form specific tissues or cell types due to the specific genetic muta-
tion, the injected rat cells take over this process entirely and as a
result, a rat organ forms inside the developing rat/mouse chi-
maera (see figure 1). These mutant mice would normally be born
lacking a pancreas or thymus, but the injection of wild type rat
PSCs allowed the development of rat organs in these chimaeras.
In theory, interspecific hybrids can be used to generate any tissue
or organ type, regardless of its complexity.
The obvious next step would be to explore whether this tech-
nology could also be applied to human PSCs. Matsunari and col-
leagues recently reported that blastocyst complementation of
Pdx1-mutant pig embryos allows the development of an entirely
donor-derived pancreas (from a different type of pig),14 demon-
strating that the Pdx1 pig could be a suitable host for the
generation of pancreas tissue. Using a larger recipient animal,
such as the pig or non-human primates, the generation of patient-
specific organs through a combination of PSC and interspecific
hybrid technology is now widely regarded as a real possibility.15
Indeed, it was recently demonstrated that human pluripotent
stem cells have the ability to form chimaeras when injected into a
host murine blastocyst.16 One problem that is still to be overcome
is the need to also ‘humanise’ the animal’s vascular system in
order to obtain organs that are indeed completely human in
order to avoid any remaining risks of rejection and cross-species
infections. This could potentially be achieved by applying a mul-
tigene blastocyst-complementation approach, in which essential
developmental regulators of vascular and lymphatic development
are mutated in concert with a mutation for the desired organ.
The biotechnology required to create chimaera organs may
take several years to perfect, and it is possible that an unforeseen
technical obstacle could prevent the use of this regenerative
technique in humans. Nonetheless, it is possible that a new
source of immunocompatible organs could be ready for clinical
Table 1 Potential solutions to the organ scarcity problem
Proposed solution Advantages (Possible) disadvantages
Increase number of living donations Minor increase in number of organs available Poses risk to donors;
Limited scope
Opt-out consent to posthumous donation Potential increase in number of organs available May not reflect donors’ wishes; not always effective
Mandatory donation after death Substantial increase in number of organs available Seen as disrespecting the dead and their families
Ignore family veto of donation from registered
donor
Respects wishes of would-be donors; increases availability
of organs
Impractical; disrespects families
Various incentives (such as tax breaks for donors) Potential increase in number of organs available Relatively untested; seen as removing altruistic
motive
Donation after cardiac death Increases pool of potential donors Donors might not be fully brain dead in some cases
Market in human organs1 Increase in pool of donors Justice concerns
Organs from transgene pigs Increase in pool of organs Sacrifice of pigs/zoonoses
Lab-grown organs No donor required Higher risk of rejection
Bionic organs No donor required Higher risk of rejection
Chimaera organs Lower risk of rejection than any other option Requires sacrifice of pigs or primates
Figure 1 Illustration of creation of
rat pancreas in mouse.
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trials by the end of this decade. Therefore, the ethical issues
raised by this fledgling biotechnology deserve consideration.
However, it should be borne in mind throughout our discussion
that research in this area is ongoing, and that considerable
uncertainty surrounds the benefits and particularly the potential
risks of chimaera organs. For the purposes of discussion here,
we focus on the use of pigs to create chimaera organs, as pigs
are regarded as the most scientifically promising source animal.
Using primates for this purpose raises particularly challenging
issues which we discuss elsewhere.17
ADVANTAGES OF USING CHIMAERA ORGANS FOR
TRANSPLANTATION
A new source of organs
The most obvious advantage of chimaera organs is that they
would provide an inexhaustible source of organs for transplant-
ation. Anyone in need of a new organ could provide iPSCs
which would be inserted in a pig embryo prior to implantation
and gestation (see box 1). After around 6 months, the resulting
pig would be sacrificed and the human organ removed and
implanted in the original donor. Hundreds of thousands of lives
would be saved every year if this technique was widely adopted,
and many more people would have their quality of life
improved if chimaera organs removed the need for dialysis.
Lower risk of organ rejection
The second advantage is that personalised chimaera organs are
likely to cause no immune response, as they will be created
from the recipient’s own DNA. This means that recipients
should no longer have to take immunosuppressant drugs for the
rest of their lives, and will be spared any of the side effects (and
the associated financial costs) of these medications. Therefore,
chimaera organs could provide an increase in the quantity, and
in the quality of organs.
Organs created using the intended recipient’s DNA are likely
to be expensive to produce, and it is possible that allogenic
organs derived from human leukocyte antigen-matched iPSC cell
lines will also be used. It is possible that a ‘two-tier’ system of chi-
maera organ provision could develop, with richer countries and
patients being able to afford autologous organs, and less well-off
nations and patients receiving inferior allogenic organs. The
equity issues this would raise are beyond the scope of this paper.
However, it should be noted that although the risk of rejection of
such allogenic therapies would be higher than in personalised
autologous therapies, they are still potentially lower than is cur-
rently the case for many organ recipients who must take which-
ever organ is available at any given time. Moreover, autologous
therapies may prove to be cheaper in the long term despite
higher initial costs, as they would avoid the need for ongoing
costs such as immunosuppressant drugs and repeated
transplantations.
ETHICAL CONCERNS ARISING FROM USE
OF CHIMAERA ORGANS
Risk of zoonosis
Objections to xenotransplantation have focused on the poten-
tial risks of zoonosis: infection with a mutated animal virus
that could then be passed on to other humans, possibly creat-
ing a pandemic.18 Zoonosis poses a public health threat to
people other than the recipient, which as such has played a
major role in halting xenotransplantation as a potential solu-
tion to the organ-scarcity problem.. However, compared with
traditional xenotransplantation, organs obtained from chi-
maeras are likely to further reduce the already small risk of
virus transfer, as the organ being transplanted would be
human despite its ‘gestation’ inside an animal host. It is
thought that precautionary monitoring of the donor-chimaeras
during their development and testing of the organ prior to
transplantation could all but eliminate the risk of accidental
transplantation of contaminated organs. However, even if the
risk of zoonoses arising from chimaera organs is almost zero,
we must also consider the magnitude of any harm that might
result.19 A deadly zoonosis could theoretically kill millions of
people, and one might question whether the benefits of creat-
ing a new source of organs is worth outweighing the potential
harms flowing from even a small risk of zoonosis. Should it be
concluded that the zoonosis risk is not prohibitive, any chi-
maera organ programme should be subject to strict conditions
including a very close monitoring to assess any ongoing threat
of zoonosis.
A related concern is the generation of cancer, rather than
viruses, in recipients of chimaera organs. The use of direct stem
cell transplants has caused cancer in some patients. However,
the use of a patient’s own stem cells to create a replacement
organ in an animal is unlikely to have this effect for two
reasons: it is not a direct transplant of cells into the patient, and
the cells involved will be heavily programmed towards specific
purposes, unlike the cells in traditional stem cell transplants.
Nonetheless, this is one other uncertainty that affects the poten-
tial use of chimaera organs.
The human features problem
While chimaera-sourced organs offer prospective advantages,
the process of creating them raises another ethically relevant
issue. Injecting human PSCs into animal embryos could theoret-
ically risk the resulting animal itself developing human physical
or mental features such as human limb development or neuronal
development. Fortunately, the chances of this happening are
remote. Even if human neurons were present in a pig brain, it is
likely that they would act like pig neurons, being influenced by
their environment rather than their genomic makeup.16
Furthermore, if any pig were found to have human gametes, it
could simply be prevented from reproducing. It should be rela-
tively simple to reduce these risks further still by knocking out
genes for neuronal and gamete development in the human PSCs
that are to be injected into the animal. Furthermore, the human
features problem is not unique to the creation of chimaera
organs, and has been raised before with regard to transgenic
animals; in these earlier debates, the risks of development of
human features were not judged sufficient to prevent use of the
new biotechnology.20 Although creating chimaera organs might
pose slightly different risks because of the different method
used to introduce human material to the animal, there is no
reason to assume that the risks of human features developing
will be any higher.
Box 1 Summary of the chimaera organ creation process
1. Induced pluripotent stem cells generated from somatic cells
taken from intended recipient
2. Human cells injected into pig embryo
3. Embryo implanted in sow
4. Gestation, birth, rearing of donor pig
5. Sacrifice of pig and transplantation of human organ into
recipient
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The most obvious ethical objection to this means of producing
organs is that (at least) one animal will be sacrificed for every
human saved. This means that hundreds of thousands of animals
will be killed each year in order to produce organs for humans if
the technology is perfected. One possible response to this argu-
ment is that it seems strange to object to using pigs to save
people’s lives when it is generally regarded as acceptable to eat
them. Eating meat is not necessary for survival, while working
organs are: as such, it actually seems more reasonable for pigs to
be used to grow life-saving organs than to provide the luxury of
meat. However, any such argument is predicated on the assump-
tion that it is ethical to eat animals in the first place. This assump-
tion still persists all over the world, but may well be mistaken;
given current prevalent attitudes, however, creating chimaera
organs seems no worse than killing animals in order to eat them.
It could also be objected that it is unfair to kill animals for their
organs when many humans refuse to donate their organs after
death. This is a valid point, but there would still be an organ scar-
city problem even if all humans were willing to donate their
organs after death, as most do not die in a way that makes organ
donation possible. Furthermore, chimaera organs could ironically
be a better medical solution than traditional transplants, due to
the problem of immune rejection of organs from other humans.
Another potential objection is that pigs can be farmed in an
ethical way, enjoying relatively happy lives before being used to
produce meat, while chimaera animals would have relatively
short lives in order to meet the supply for organs and would
also have to be kept in very sterile conditions, with potential
adverse effects on their well-being. There is also a possibility
that genetically modified animals might suffer more than
‘normal’ animals, particularly if the developing human organ
caused them discomfort. For example, the rat pancreas grown in
the rat-mouse chimaeras maintained blood glucose levels at rat
physiological levels, demonstrating that species-specific organ
physiological parameters can dominate the entire organism.
Nonetheless, given that society generally accords humans
greater importance than animals, it appears that creating organs
in this way would not threaten animal welfare in a new or
unique way.
Finally, it should also be remembered that hundreds or
perhaps thousands of animals will also need to be sacrificed as
part of ongoing research into chimaera organs. While this is not
very many in comparison with the number that will be sacrificed
if the technique becomes widely used in humans, it should still
be asked whether it is legitimate to use animals for this type of
research. At first glance it might appear obvious that using them
for research into a technology that could save dozens of human
lives every day is more ethical than using them for research into
a faint chance that a new drug might help a few dozen patients
per year. However, there are two rebuttals to this point. First,
the many uncertainties surrounding the creation of chimaera
organs means that success is no more guaranteed than in any
other animal research. Second, it could be argued that it is not
in animals’ interests to contribute to the perfection of chimaera
organ biotechnology, and that it is actually against the interests
of future animals. In normal medical research on animals, no
more animals are used for testing or killed once the drug
reaches the stage of clinical trials. In the case of chimaera
organs, however, the success of clinical trials would mean that
thousands more animals will be killed every year as part of the
organ production process. In terms of animal solidarity, chi-
maera organ research is therefore worse than most medical
research involving animals. However, from the human
perspective, this type of research meets the requirements of pro-
portionality and subsidiarity much more easily than most animal
research, though other potential sources of organs (see table 1)
should also be pursued. Given the possibility that these other
avenues might not be successful, it would be irresponsible to
discontinue current funding for chimaera organ research. (If a
stricter definition of subsidiarity were adopted, it might be con-
cluded that chimaera organ research should only continue if all
other options have already been tried. However, we regard it as
reasonable to adopt a more lenient definition that favours simul-
taneous pursuit of different organ sources.)
Human dignity
Finally, is human dignity threatened simply by the very creation
of human/animal chimaeras? As is often the case when the
concept of dignity is put to use in bioethics, it depends very
much on what is meant by human dignity: while some will
argue that it is against human dignity to let people die when we
could save them with chimaera organs, it has also been sug-
gested that the creation of chimaeras could threaten human
dignity by mixing our basic constituents with those of
animals.21 Similar arguments have previously been found to be
flawed,20 for a variety of reasons. Human dignity was raised as a
concern in 2007 in response to the creation of human/rabbit
chimaera embryos, even though any such embryos were to be
destroyed within 14 days of creation and had only 0.04%
animal DNA.22 It has been claimed that “to produce creatures
that blur the boundaries between humans and animals could
threaten to undermine the concept of human dignity since it is a
dignity specifically reserved to humankind”.23 This argument
appears to be camouflage for concerns about ‘playing God’ or
the feelings of revulsion that the idea of chimaeras induces in
many people. Just as revulsion does not constitute a sound
reason for objecting to something, human dignity does not
appear to be threatened merely by the act of creating human
organs inside animals. Similarly, we cannot infer any ethical
judgment from the fact that we would be ‘crossing species
boundaries’; doing so might be unnatural, but so is much of
human endeavour. It is important to make the distinction
between human dignity arguments based on the mere fact of
mixing between species, and dignity arguments based on the
potentially unethical consequences of creating chimaeras. While
an animal with human mental features might seem a threat to
human dignity, the precautions taken to prevent human neur-
onal (or reproductive) development should minimise the risk of
this happening. In the absence of any adverse consequences,
objections based on human dignity are deprived of most of their
force. As the Academy of Medical Sciences has stated:
It has long been accepted that the dignity of man does not rule
out many ways in which animal and human materials are com-
bined….humans are not demeaned by the incorporation of parts
of non-human animals (such as heart valves from pigs) through
xenotransplantation, though it is possible to object to this prac-
tice on other grounds. Similarly, therefore, the creation by
another form of xenotransplantation of animals which include
significant human elements cannot be held to threaten human
dignity just because it humanises the animals involved.21
Of course, anyone who did think that it violated human
dignity to accept an organ that had been grown in an animal (or
who had concerns about animal welfare) could simply refuse to
accept one, although it may well be the case that weakly felt
symbolic concerns about dignity might be abandoned if no
other organ could be found. (This is not to suggest that
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everyone would abandon all ethical concerns if faced with death,
but rather that many people’s concerns about human dignity
appear rather ephemeral, and that they might evaporate entirely
or be refocused into concerns about the indignity of dying in the
face of certain death.) Perhaps the most persuasive argument con-
cerning human dignity is actually not that the proposed technol-
ogy reduces us to mix our DNA with theirs, but that it is
undignified for higher animals such as humans to instrumentalise
and kill lesser animals in this way when there are other potential
sources of organs. This is really an argument about animal
welfare rephrased as one concerning human dignity. However, as
already mentioned, all countries currently instrumentalise animals
routinely, and using them to save lives may be ethically preferable
to using them for non-essential purposes.
CONCLUSION
We have explored the potential harms and benefit of creating
chimaera organs and analysed the various ethical issues raised
by this new biotechnology. Organs from chimaeras have the
potential to solve the current organ scarcity problem and save
hundreds of thousands of lives each year, and to provide a limit-
less supply of organs that will not trigger any immune reaction.
This new type of regenerative medicine therefore has the poten-
tial to provide organs to those on the waiting list, and to
provide better organs to those who have already received an
organ. However, more research is required in order to clarify
several uncertainties about viability and safety, and several con-
cerns remain regarding the human features problem, animal
welfare and human dignity. These ethical issues must be debated
and addressed before such organs are created; doing so will
require significant engagement with the public. Finally, the inev-
itable violation of animal welfare entails that creating chimaera
organs for transplantation would only be acceptable if no alter-
native solutions to the organ scarcity problem are found;
research into finding such solutions will therefore remain
necessary.
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